Approximately 1.6 million new cases of lung cancer are diagnosed each year throughout the
world. In many countries, the mortality related to lung cancer continues to rise. The outcomes …

Background Previous studies have demonstrated the efficacy and safety of bevacizumab in
the treatment of non-small-cell lung cancer (NSCLC). Methods Summary data from …

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy
reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI …

Background Several studies have shown the efficacy, tolerability, and ease of administration
of pemetrexed—an antifolate antineoplastic agent—in patients with advanced non-small-cell …

Lung cancer is the leading cause of cancer-related deaths in the world, and non-small-cell
lung cancer (NSCLC) accounts for 80% of cases. MicroRNA-21 (miR-21) expression is …

Background Treatment options after first-line chemotherapy are limited in non-small cell lung
cancer (NSCLC). Belagenpumatucel-L is a therapeutic vaccine comprised of 4 transforming …

Most patients with non–small cell lung cancer (NSCLC) are diagnosed with advanced
cancer. These guidelines only include information about stage IV NSCLC. Patients with …

Platinum-based chemotherapy remains the standard-of-care for most patients affected by
advanced non-small cell lung cancer (NSCLC). The platinum compounds currently used in …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

BACKGROUND: It has been reported that antidiabetic drugs affect the risk of cancer and the
prognosis of patients with diabetes, but few studies have demonstrated the influence of …